Single-Cell Studies in Autoimmune Diseases: Insights from scRNA-seq
A systematic review analyzed various single-cell RNA sequencing (scRNA-seq) studies across diseases like multiple sclerosis. It highlighted key inflammatory programs, particularly involving immune signaling and interactions. However, the evidence regarding shared cell states and regulatory mechanisms is limited, leaving questions about their roles in disease pathology open.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This research is crucial as it uses state-of-the-art techniques to profile immune responses, enhancing our understanding of autoimmune diseases like multiple sclerosis and potentially guiding future research. However, definitive links between these findings and specific pathogenic mechanisms are unclear.
What this does not prove
The review notes challenges such as cohort biases, reproducibility issues, and computational complexities that hinder practical application in clinical settings. It also points to privacy concerns with single-cell profiling data.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-14
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (9)
study designThis review critically examines recent single-cell studies in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, type 1 diabetes, and multiple sclerosis.
peer reviewedSingle-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.
findingsSingle-cell RNA sequencing (scRNA-seq) enables transcriptomic profiling at cellular resolution, while complementary multimodal, receptor-repertoire, epigenomic, and spatial approaches can link cellular states to protein phenotype, clonal architecture, regulatory programs, and tissue context.
findingsAcross the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain.
findingsAcross the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain.
findingsAcross the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain.
limitationsWe further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation.
limitationsWe further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation.
publication datePublication date: 2026-10-14
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.